智通财经APP获悉，5月12日，药物临床试验登记与信息公示平台显示，辉瑞(PFE.US)在国内启动了一项PF-08046054针对实体瘤患者的Ⅰ期临床。PF-08046054(SGN-PDL1V)是辉瑞收购Seagen获得的一款靶向PD-L1的ADC。

截图来源：药物临床试验登记与信息公示平台

这项Ⅰ期临床旨在评估PF-08046054作为单药治疗晚期实体恶性肿瘤受试者，以及作为联合治疗用于转移性或不可切除头颈部鳞状细胞癌(HNSCC)或非小细胞肺癌(NSCLC)受试者的安全性、耐受性、PK和抗肿瘤活性。研究的主要终点指标是安全性，次要终点指标是有效性。

Insight数据库显示，全球目前共有2款靶向PD-L1的ADC进入临床阶段。除了辉瑞的PF-08046054，另外一款为宜联生物/复宏汉霖的HLX43，目前正在开展Ⅱ期临床阶段。此外，还有三款靶向PD-L1的双靶点ADC进入临床，分别来自信达、映恩、康宁杰瑞。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.